uniQure NV
Cerrado
48.16 79.84
Resumen
Variación precio
24h
Mínimo
26.93
Máximo
49.68
Ingresos | -16M -54M |
|---|---|
Ventas | -2M 3.6M |
BPA | -0.73 |
Margen de beneficios | -1,502.948 |
Empleados | 221 |
EBITDA | 13M -36M |
Recomendaciones | Compra Fuerte |
|---|---|
Estimación a 12 Meses | +47.76% upside |
Próximas Ganancias | 28 jul 2026 |
|---|
Capitalización Mercado | 454M 1.8B |
|---|---|
Apertura anterior | -31.68 |
Cierre anterior | 48.16 |
uniQure NV Gráfico
Resultados pasados no son un indicador fiable de resultados futuros.
Acerca de uniQure NV
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
